Market closed
Cyclo Therapeutics/$CYTH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cyclo Therapeutics
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Ticker
$CYTH
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
8
Website
CYTH Metrics
BasicAdvanced
$22M
-
-$0.92
-0.49
-
Price and volume
Market cap
$22M
Beta
-0.49
52-week high
$1.79
52-week low
$0.55
Average daily volume
3M
Financial strength
Current ratio
0.174
Quick ratio
0.06
Long term debt to equity
-0.053
Total debt to equity
-90.588
Management effectiveness
Return on assets (TTM)
-284.27%
Return on equity (TTM)
341.45%
Valuation
Price to revenue (TTM)
23.633
Price to book
-1.62
Price to tangible book (TTM)
-1.62
Price to free cash flow (TTM)
-0.914
Growth
Revenue change (TTM)
-8.52%
Earnings per share change (TTM)
-38.93%
3-year revenue growth (CAGR)
-8.76%
3-year earnings per share growth (CAGR)
-31.13%
What the Analysts think about CYTH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cyclo Therapeutics stock.
CYTH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CYTH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CYTH News
AllArticlesVideos
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
Business Wire·6 days ago
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cyclo Therapeutics stock?
Cyclo Therapeutics (CYTH) has a market cap of $22M as of February 26, 2025.
What is the P/E ratio for Cyclo Therapeutics stock?
The price to earnings (P/E) ratio for Cyclo Therapeutics (CYTH) stock is 0 as of February 26, 2025.
Does Cyclo Therapeutics stock pay dividends?
No, Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Cyclo Therapeutics dividend payment date?
Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Cyclo Therapeutics?
Cyclo Therapeutics (CYTH) has a beta rating of -0.49. This means that it has an inverse relation to market volatility.